Get the Stockscreener App
3.85
1.32%
0.05
After Hours:
3.85
Annovis Bio Inc stock is traded at $3.85, with a volume of 443.87K.
It is up +1.32% in the last 24 hours and down -15.38% over the past month.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
See More
Previous Close:
$3.80
Open:
$3.81
24h Volume:
443.87K
Relative Volume:
0.24
Market Cap:
$102.04M
Revenue:
-
Net Income/Loss:
$-30.26M
P/E Ratio:
-1.8873
EPS:
-2.04
Net Cash Flow:
$-24.69M
1W Performance:
+11.27%
1M Performance:
-15.38%
6M Performance:
+63.14%
1Y Performance:
-28.04%
1-Day Range:
$3.75
$3.94
1-Week Range:
$3.26
$3.94
52-Week Range:
$1.11
$5.57
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
3.85 | 100.71M | 0 | -30.26M | -24.69M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
2026 world cup match preview guide: Will Annovis Bio Inc. stock attract ESG investors2026 world cup usa national team qualification defensive leaders counter attacking group prediction tactical review - Улправда
Breakout Watch: How Annovis Bio Inc stock reacts to oil pricesOptions Play & Reliable Intraday Trade Alerts - moha.gov.vn
Annovis Bio stock rating cut to hold at D. Boral Capital - MSN
History Review: Is Annovis Bio Inc stock attractive for growth ETFsJuly 2025 Update & Breakout Confirmation Alerts - moha.gov.vn
Annovis sets investor webinar as neurodegeneration pipeline reaches inflection - MSN
Annovis Bio, Inc. (NYSE:ANVS) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Published on: 2025-12-25 20:53:49 - moha.gov.vn
Annovis Launches 3-Year Parkinson’s Study to Test Long-Term Promise of Drug - MyChesCo
Annovis Sets Investor Webinar as Neurodegeneration Pipeline Reaches Inflection - MyChesCo
Inflation Data: Is Annovis Bio Inc. stock positioned for secular growthTrade Risk Summary & Verified Stock Trade Ideas - Улправда
Why analysts remain bullish on Annovis Bio Inc. stockJuly 2025 Technicals & Short-Term Swing Trade Alerts - Улправда
Is Annovis Bio Inc. stock positioned for secular growthMarket Activity Recap & AI Driven Price Predictions - Улправда
Volume Summary: Can Annovis Bio Inc. stock hold up in economic slowdownShort Setup & Technical Pattern Alert System - moha.gov.vn
What technical patterns form on Annovis Bio Inc. stock chartsTrade Entry Report & Technical Confirmation Alerts - Улправда
How Annovis Bio Inc. stock reacts to oil pricesJuly 2025 Big Picture & Reliable Trade Execution Plans - DonanımHaber
Why Annovis Bio Inc. stock appears on watchlistsJuly 2025 Summary & Stepwise Trade Signal Guides - DonanımHaber
Annovis Plans 36-Month Extension Study To Further Evaluate Buntanetap In Parkinson's - Nasdaq
Is Annovis Bio Inc. stock a smart buy before Fed meetingJuly 2025 Spike Watch & AI Driven Price Forecasts - DonanımHaber
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients - The Manila Times
Annovis Bio to launch long-term Parkinson’s drug study in January - Investing.com India
Annovis Bio to launch long-term Parkinson’s drug study in January By Investing.com - Investing.com South Africa
Annovis Bio to Launch Long-Term Open-Label Study for Buntanetap in Parkinson's Disease Patients Starting January 2026 - Quiver Quantitative
Annovis Bio Advances Long-Term Buntanetap Safety Study in Parkinson’s Disease - TipRanks
Will Annovis Bio Inc. stock attract ESG investorsTrade Performance Summary & Real-Time Stock Entry Alerts - Улправда
Annovis Bio advances long-term buntanetap safety study in Parkinson’s disease - MSN
Annovis to Host Corporate Update Webinar on January 28, 2026 - GlobeNewswire
Alzheimer's drug hunt learns from cancer fight's multi-target playbook - Reuters
Parkinson’s Breakthrough? New Data Shows Drug May Reverse Cognitive Decline - MSN
Keeping Neurodegeneration Top Of Mind: Is Annovis Bio's Pipeline Progress Enough? - RTTNews
ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Annovis Bio director Hoffman buys $193,794 in shares By Investing.com - Investing.com UK
Annovis Bio (NYSE:ANVS) Director Purchases $193,950.00 in Stock - MarketBeat
Annovis Bio director Hoffman buys $193,794 in shares - Investing.com India
Annovis Bio (ANVS) director reports 45,000-share insider purchase at around $4 - Stock Titan
Chmn Hoffman Buys 45,000 ($193.8K) Of Annovis Bio Inc [ANVS] - TradingView — Track All Markets
Published on: 2025-12-08 04:36:17 - moha.gov.vn
Annovis Bio Inc. (ANVS) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Can Annovis Bio Inc. stock deliver consistent EPS growth2025 Retail Activity & High Yield Stock Recommendations - Newser
Is Annovis Bio Inc. stock a top hedge fund pickEarnings Beat & High Conviction Buy Zone Picks - Newser
Why institutional investors increase stakes in Annovis Bio Inc. stockEarnings Performance Report & Capital Efficiency Focused Ideas - Newser
Why Annovis Bio Inc. stock fits value portfoliosJuly 2025 Summary & Low Risk High Reward Ideas - Newser
Why Annovis Bio Inc. stock is a must watch tickerEarnings Risk Report & Weekly Watchlist for Consistent Profits - Newser
Annovis Bio (ANVS) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
How Annovis Bio Inc. stock compares with top peers2025 Price Targets & Weekly Stock Breakout Alerts - Newser
How geopolitical risks impact Annovis Bio Inc. stockWeekly Trade Recap & Weekly Return Optimization Alerts - Newser
Annovis Bio (ANVS) Stock Analysis Report | Financials & Insights - Benzinga
Annovis Bio to Present Comprehensive Buntanetap Data at Parkinson Study Group Meeting - citybuzz
Who are in the management team of Annovis Bio, Inc.? - Markets Mojo
Annovis Bio, Inc. to Present At the 2025 Annual Meeting of the Parkinson Study Group - marketscreener.com
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group - The Manila Times
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):